Boehringer Ingelheim and OSE Immunotherapeutics Expand Collaboration

In a recent announcement, Boehringer Ingelheim and the clinical-stage biotechnology company OSE Immunotherapeutics SA (OSE) have expanded their existing collaboration. Two new co-development projects targeting first-in-class therapies for oncology and cardiorenal metabolic (CRM) diseases will be added to the ongoing anti-SIRPα immuno-oncology program.

The first project involves expanding the therapeutic assessment of the existing collaboration assets to cover a broader patient population. The second project concerns the acquisition of new assets - the anti-SIRPα cancer immunotherapy compounds BI 765063 and BI 770371. These compounds are currently in Phase I clinical trials for advanced solid tumors and will now also be developed for CRM diseases.

Additionally, a new clinical-stage project based on OSE's proprietary cisMab anti-PD-1/cytokine platform for immune cell activation therapy will be initiated through asset acquisition. This platform has the potential to further enrich Boehringer Ingelheim's pipeline of innovative immune-modulatory oncology therapies.

The expanded collaboration strengthens Boehringer Ingelheim's product pipeline and reflects the company's unwavering commitment to exploring and developing new therapies to address unmet patient needs, including in the areas of CRM diseases and oncology.

Under the terms of the agreement, OSE Immunotherapeutics will receive an upfront payment of €13.5 million and potential near-term milestone payments of up to €17.5 million for the acquisition of the new clinical-stage cisMab anti-PD-1/cytokine platform asset. Regarding the two ongoing anti-SIRPα programs, BI 765063 and BI 770371, the parties have reached a partial buy-out agreement, with Boehringer Ingelheim making a one-time payment of €25.3 million.

This expanded collaboration underscores the shared commitment of Boehringer Ingelheim and OSE Immunotherapeutics to advancing innovative therapies and addressing the significant unmet medical needs in oncology and cardiorenal metabolic diseases, which affect the lives of over 1 billion people globally.